• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在免疫疗法中使用超细胞因子、免疫细胞因子、衔接细胞因子和其他合成细胞因子。

The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.

机构信息

CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.

Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, 518055, Shenzhen, China.

出版信息

Cell Mol Immunol. 2022 Feb;19(2):192-209. doi: 10.1038/s41423-021-00786-6. Epub 2022 Jan 4.

DOI:10.1038/s41423-021-00786-6
PMID:35043005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8803834/
Abstract

Cytokines exert powerful immunomodulatory effects that are critical to physiology and pathology in humans. The application of natural cytokines in clinical studies has not been clearly established, and there are often problems associated with toxicity or lack of efficacy. The key reasons can be attributed to the pleiotropy of cytokine receptors and undesired activation of off-target cells. With a deeper understanding of the structural principles and functional signals of cytokine-receptor interactions, artificial modification of cytokine signaling through protein engineering and synthetic immunology has become an increasingly feasible and powerful approach. Engineered cytokines are designed to selectively target cells. Herein, the theoretical and experimental evidence of cytokine engineering is reviewed, and the "supercytokines" resulting from structural enhancement and the "immunocytokines" generated by antibody fusion are described. Finally, the "engager cytokines" formed by the crosslinking of cytokines and bispecific immune engagers and other synthetic cytokines formed by nonnatural analogs are also discussed.

摘要

细胞因子发挥着强大的免疫调节作用,对人类的生理和病理至关重要。天然细胞因子在临床研究中的应用尚未明确确立,而且常常存在毒性或缺乏疗效的问题。其关键原因可归因于细胞因子受体的多效性和对非靶细胞的意外激活。随着对细胞因子-受体相互作用的结构原理和功能信号的深入了解,通过蛋白质工程和合成免疫学对细胞因子信号进行人工修饰已成为一种越来越可行和强大的方法。工程细胞因子被设计为选择性地靶向细胞。本文综述了细胞因子工程的理论和实验证据,并描述了结构增强产生的“超级细胞因子”和抗体融合产生的“免疫细胞因子”。最后,还讨论了细胞因子与双特异性免疫结合物交联形成的“交联细胞因子”以及其他非天然类似物形成的合成细胞因子。

相似文献

1
The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.在免疫疗法中使用超细胞因子、免疫细胞因子、衔接细胞因子和其他合成细胞因子。
Cell Mol Immunol. 2022 Feb;19(2):192-209. doi: 10.1038/s41423-021-00786-6. Epub 2022 Jan 4.
2
Insights into cytokine-receptor interactions from cytokine engineering.细胞因子工程对细胞因子-受体相互作用的见解。
Annu Rev Immunol. 2015;33:139-67. doi: 10.1146/annurev-immunol-032713-120211. Epub 2014 Dec 10.
3
Cytokine/Antibody Fusion Protein Design and Evaluation.细胞因子/抗体融合蛋白的设计与评估。
Curr Protoc. 2024 May;4(5):e1061. doi: 10.1002/cpz1.1061.
4
Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy.嵌合细胞因子药物在癌症免疫治疗中的现状与展望。
Clin Cancer Res. 2024 May 15;30(10):2025-2038. doi: 10.1158/1078-0432.CCR-23-1160.
5
Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.采用 IL-2 细胞因子靶向肿瘤的抗癌疗法:固有、适应性和免疫抑制细胞在抗肿瘤疗效中的贡献。
Front Immunol. 2018 Dec 18;9:2905. doi: 10.3389/fimmu.2018.02905. eCollection 2018.
6
The present and future of immunocytokines for cancer treatment.免疫细胞因子在癌症治疗中的现状和未来。
Cell Mol Life Sci. 2022 Sep 6;79(10):509. doi: 10.1007/s00018-022-04514-9.
7
Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.工程化新城疫病毒作为免疫检查点抑制剂和免疫细胞因子瘤内递送的溶瘤载体。
J Virol. 2020 Jan 17;94(3). doi: 10.1128/JVI.01677-19.
8
Immunocytokines: a promising approach to cancer immunotherapy.免疫细胞因子:癌症免疫治疗的一种有前景的方法。
Pharmacol Ther. 1998 Dec;80(3):277-92. doi: 10.1016/s0163-7258(98)00033-3.
9
Antibody fusions with immunomodulatory proteins for cancer therapy.抗体融合免疫调节蛋白用于癌症治疗。
Pharmacol Ther. 2015 Oct;154:57-66. doi: 10.1016/j.pharmthera.2015.07.001. Epub 2015 Jul 3.
10
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.抗体-细胞因子融合蛋白:具有免疫调节特性的生物制药,用于癌症治疗。
Adv Drug Deliv Rev. 2019 Feb 15;141:67-91. doi: 10.1016/j.addr.2018.09.002. Epub 2018 Sep 7.

引用本文的文献

1
Cytokine Therapy in Bladder Cancer: Mechanisms, Efficacy, and Future Prospects.膀胱癌的细胞因子治疗:机制、疗效及未来前景
Curr Issues Mol Biol. 2025 Apr 15;47(4):278. doi: 10.3390/cimb47040278.
2
The biology of interleukin-6 family cytokines is regulated by glycosylation.白细胞介素-6家族细胞因子的生物学特性受糖基化作用调控。
Biochem J. 2025 May 21;482(10):535-551. doi: 10.1042/BCJ20240769.
3
Evaluation of the multivalent immune protective effects of the outer membrane protein VF17320, and its DNA and IgY antibody vaccines in fish.鱼类中外膜蛋白VF17320及其DNA和IgY抗体疫苗的多价免疫保护作用评估。
Front Vet Sci. 2025 Jun 18;12:1586258. doi: 10.3389/fvets.2025.1586258. eCollection 2025.
4
Cytokine Signatures as Biomarkers of Clinical Remission in Rheumatoid Arthritis.细胞因子特征作为类风湿关节炎临床缓解的生物标志物
J Inflamm Res. 2025 Jun 25;18:8345-8356. doi: 10.2147/JIR.S527601. eCollection 2025.
5
Synergistic therapy for pancreatic cancer by deactivating cancer-associated fibroblasts and driving T-cell migration into tumor microenvironment using nanochaperone delivery system.通过使用纳米伴侣递送系统失活癌症相关成纤维细胞并驱动T细胞迁移至肿瘤微环境来实现胰腺癌的协同治疗。
Bioact Mater. 2025 Jun 11;52:287-299. doi: 10.1016/j.bioactmat.2025.06.010. eCollection 2025 Oct.
6
In vitro and in vivo evaluation of chemically synthesized, receptor-biased interleukin-4 and photocaged variants.化学合成的、受体偏向性白细胞介素-4及其光笼变体的体外和体内评价
Sci Adv. 2025 Jun 27;11(26):eadw9755. doi: 10.1126/sciadv.adw9755. Epub 2025 Jun 25.
7
Nanoparticle approaches for manipulating cytokine delivery and neutralization.用于调控细胞因子递送与中和的纳米颗粒方法。
Front Immunol. 2025 Jun 10;16:1592795. doi: 10.3389/fimmu.2025.1592795. eCollection 2025.
8
-Cyclooctene-caged-IL-1β immunocytokine-constructs ligated to unmodified nanobodies allow click-2-release-based control of cytokine activity.与未修饰的纳米抗体连接的环辛烯笼化白细胞介素-1β免疫细胞因子构建体允许基于点击-2-释放的细胞因子活性控制。
RSC Chem Biol. 2025 Jun 4. doi: 10.1039/d5cb00113g.
9
Tyrosinase in melanoma inhibits anti-tumor activity of PD-1 deficient T cells.黑色素瘤中的酪氨酸酶会抑制PD-1缺陷型T细胞的抗肿瘤活性。
BMC Biol. 2025 May 15;23(1):135. doi: 10.1186/s12915-025-02237-4.
10
Trifunctional antibody-cytokine fusion protein formats for tumor-targeted combination of IL-15 with IL-7 or IL-21.用于将IL-15与IL-7或IL-21进行肿瘤靶向联合的三功能抗体-细胞因子融合蛋白形式
Front Immunol. 2025 Apr 30;16:1498697. doi: 10.3389/fimmu.2025.1498697. eCollection 2025.

本文引用的文献

1
Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells.IL-12 和 IL-23 受体共享的结构基础揭示了调节 T 细胞与 NK 细胞作用的途径。
Cell. 2021 Feb 18;184(4):983-999.e24. doi: 10.1016/j.cell.2021.01.018.
2
Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy.针对肿瘤反应性 T 细胞的 IL-21 可增强记忆 T 细胞应答和抗 PD-1 抗体治疗。
Nat Commun. 2021 Feb 11;12(1):951. doi: 10.1038/s41467-021-21241-0.
3
Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers.三特异性杀手结合物 161519 增强了自然杀伤细胞的功能,并针对 CD19 阳性癌症提供了抗肿瘤活性。
Cancer Biol Med. 2020 Nov 15;17(4):1026-1038. doi: 10.20892/j.issn.2095-3941.2020.0399. Epub 2020 Dec 15.
4
Immunopathobiology and therapeutic targets related to cytokines in liver diseases.与肝脏疾病相关细胞因子的免疫病理生物学及治疗靶点。
Cell Mol Immunol. 2021 Jan;18(1):18-37. doi: 10.1038/s41423-020-00580-w. Epub 2020 Nov 17.
5
Human immunology and immunotherapy: main achievements and challenges.人类免疫学和免疫疗法:主要成就和挑战。
Cell Mol Immunol. 2021 Apr;18(4):805-828. doi: 10.1038/s41423-020-00530-6. Epub 2020 Sep 2.
6
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy.白细胞介素-18 结合蛋白是一种分泌型免疫检查点和白细胞介素-18 免疫治疗的障碍。
Nature. 2020 Jul;583(7817):609-614. doi: 10.1038/s41586-020-2422-6. Epub 2020 Jun 24.
7
Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.工程化的 IL-21 细胞因子突变体与抗 PD-1 抗体融合可改善 CD8+T 细胞功能和抗肿瘤免疫。
Front Immunol. 2020 May 8;11:832. doi: 10.3389/fimmu.2020.00832. eCollection 2020.
8
Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.下一代基于双特异性抗体的抗肿瘤治疗药物面临的挑战与策略
Cell Mol Immunol. 2020 May;17(5):451-461. doi: 10.1038/s41423-020-0417-8. Epub 2020 Apr 20.
9
T cell-engaging therapies - BiTEs and beyond.T 细胞结合疗法——双特异性抗体和其他疗法。
Nat Rev Clin Oncol. 2020 Jul;17(7):418-434. doi: 10.1038/s41571-020-0347-5. Epub 2020 Apr 2.
10
The transcription factor RelB restrains group 2 innate lymphoid cells and type 2 immune pathology in vivo.转录因子 RelB 抑制体内 2 型固有淋巴细胞和 2 型免疫病理。
Cell Mol Immunol. 2021 Jan;18(1):230-242. doi: 10.1038/s41423-020-0404-0. Epub 2020 Mar 19.